Business Wire

SoftServe Offers Complimentary Assessment for In-Store Social Distancing Solution

28.7.2020 14:00:00 EEST | Business Wire | Press release

Share

SoftServe, a leading digital authority and consulting company, is offering a complimentary assessment through September 30, 2020 for its In-Store Social Distancing Solution, a cloud-based computer vision and mobile app solution that offers retailers a 360-degree customer view through AI-powered advanced analytics to support value-led decision making through actionable insights. This solution enables stores to provide a secure shopping environment for customers and employees while remaining compliant with government mandated social distancing regulations, as well as track customer engagement to understand future buying dynamics and optimize store layouts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005019/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SoftServe's In-Store Social Distancing Solution mobile interface. (Photo: Business Wire)

Computer vision is a form of artificial intelligence (AI) that trains computers to interpret and understand digital images from cameras and videos. Computers can ‘learn’ to accurately identify and classify objects, and then react to and report on what they ‘see’. It’s a rapidly growing platform for real-time store management and enhanced operations. By 2021, 40% of retailers will implement computer vision in their customer service and support workflow, and vendors employing computer vision in retail will see a 20% lift in conversion.1

“SoftServe’s in-store social distancing solution is bridging a critical gap for retailers, ensuring a safe shopping environment through the COVID-19 pandemic while providing a valuable long-term solution for continual security, future growth, and consumer engagement,” said Valentyn Kropov, VP, client success at SoftServe. “Our solution works with your existing in-store equipment and can be ‘retrained’ around future scenarios, giving you a foundation on which to optimize store operations and customer experience for years to come.”

Ensure Customer and Employee Safety and Social Distancing Regulatory Compliance

  • Mask and Temperature Detection—detect if patrons are wearing masks and scan customers’ temperatures with an infrared thermometer upon entry.
  • Manage Store Capacity—count the number of patrons entering and exiting the store and provide entry permission alerts and QR code vouchers through a mobile app.
  • Avoid Physical Lines—track designated distance between queued customers, provide department wait times and information through digital signage, and allow patrons to reserve spots in line.

Identify and Understand Customers’ Buying Dynamics

  • Real-Time Data Processing—get actionable insights in the moment with a self-learning system that fully automates data collection.
  • In-Store Customer Tracking—understand your customers’ in-store movements and product engagement better with demographics and heatmap analysis.
  • Create More Immersive Shopping Experiences—learn customer interaction points and deploy AI-driven dynamic in-store advertisements. Use location analytics to optimize store layout and product positioning around customer preferences.

SoftServe’s In-Store Social Distancing Solution integrates with a store’s existing CCTV infrastructure and software platforms and can be rapidly deployed to be up and running in a couple of weeks. It’s designed to be scalable for hundreds of stores, yet is customizable around the specific business needs of each individual store.

Book your complimentary assessment and demo through the end of September today. Contact RetailDemo@softserveinc.com for a timely evaluation of your store environment to identify the most cost-efficient solution.

1 Nick Ingelbrecht, Anthony Bradley “Emerging Technologies: Top Advanced Computer Vision Use Cases for Retail”, Gartner, April 23, 2020

About SoftServe

SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.

SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.

Visit our website, blog, LinkedIn, Facebook, and Twitter pages.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
512-796-7358

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye